India's drug regulators are increasing monitoring of weight-loss drugs, particularly GLP-1 receptor agonists, as safety concerns arise with the introduction of cheaper generic versions. The Indian Pharmacopoeia Commission (IPC) has been tasked with systematically collecting and reviewing reports of adverse events linked to these medications. This initiative aims to enhance post-marketing surveillance and ensure that safety signals are promptly documented and acted upon. With the patent for semaglutide recently expiring, the market for weight-loss drugs is poised for significant growth, projected to reach $27.4 billion by 2025, driven by rising health concerns. Nearly one in four adults in India is classified as obese, and the country ranks second globally in the number of overweight and obese children. In response to misleading advertising practices, regulators have emphasized the need for ethical marketing standards and have empowered local authorities to enforce compliance. The IPC will prepare periodic safety reviews to address emerging risks and protect vulnerable populations from aggressive promotional tactics.